Literature DB >> 11509951

Radio-responsive recA promoter significantly increases TNFalpha production in recombinant clostridia after 2 Gy irradiation.

S Nuyts1, L Van Mellaert, J Theys, W Landuyt, E Bosmans, J Anné, P Lambin.   

Abstract

One of the major problems with gene therapy today is the lack of tumour specificity. The use of anaerobic apathogenic clostridia as a gene transfer system can target anoxic areas within the tumour. These bacteria can be genetically modified to express therapeutic proteins such as TNFalpha locally in the tumour. As shown in our results, ionising irradiation can be used in clostridia to activate genes encoding cytotoxic agents under control of a radiation-inducible promoter. A 44% significant increase (P < 0.05) in TNFalpha secretion was seen 3.5 h after a single dose of 2 Gy. A second dose of 2 Gy was also capable of repeating gene activation and gave a significant increase of TNFalpha production of 42% (P < 0.05). These results provide evidence that spatial and temporal control of gene expression can be achieved using a radio-inducible promoter. Repetitive gene activation was feasible with a second dose of 2 Gy, indicating that fractionated radiotherapy could lead to repeated gene induction resulting in prolonged and enhanced protein expression. Gene targeting by ionising radiation could thus provide a new means of increasing the therapeutic ratio in cancer treatment.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11509951     DOI: 10.1038/sj.gt.3301499

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  31 in total

1.  Can engineered bacteria help control cancer?

Authors:  R K Jain; N S Forbes
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-18       Impact factor: 11.205

Review 2.  Bugs as drugs for cancer.

Authors:  Eleanor J Cheadle; Andrew M Jackson
Journal:  Immunology       Date:  2002-09       Impact factor: 7.397

Review 3.  Regulatable gene expression systems for gene therapy applications: progress and future challenges.

Authors:  S Goverdhana; M Puntel; W Xiong; J M Zirger; C Barcia; J F Curtin; E B Soffer; S Mondkar; G D King; J Hu; S A Sciascia; M Candolfi; D S Greengold; P R Lowenstein; M G Castro
Journal:  Mol Ther       Date:  2005-08       Impact factor: 11.454

Review 4.  Plasmid engineering for controlled and sustained gene expression for nonviral gene therapy.

Authors:  Ethlinn V B van Gaal; Wim E Hennink; Daan J A Crommelin; Enrico Mastrobattista
Journal:  Pharm Res       Date:  2006-05-26       Impact factor: 4.200

Review 5.  Regulatable gene expression systems for gene therapy.

Authors:  Nuria Vilaboa; Richard Voellmy
Journal:  Curr Gene Ther       Date:  2006-08       Impact factor: 4.391

6.  Advances in bacterial cancer therapies using synthetic biology.

Authors:  Tiffany Chien; Anjali Doshi; Tal Danino
Journal:  Curr Opin Syst Biol       Date:  2017-05-23

Review 7.  Tumour-targeting bacteria engineered to fight cancer.

Authors:  Shibin Zhou; Claudia Gravekamp; David Bermudes; Ke Liu
Journal:  Nat Rev Cancer       Date:  2018-12       Impact factor: 60.716

Review 8.  Synthetic biology approaches in drug discovery and pharmaceutical biotechnology.

Authors:  Heinz Neumann; Petra Neumann-Staubitz
Journal:  Appl Microbiol Biotechnol       Date:  2010-04-16       Impact factor: 4.813

Review 9.  Bacterial therapies: completing the cancer treatment toolbox.

Authors:  Adam T St Jean; Miaomin Zhang; Neil S Forbes
Journal:  Curr Opin Biotechnol       Date:  2008-09-18       Impact factor: 9.740

10.  Tumour-targeted delivery of TRAIL using Salmonella typhimurium enhances breast cancer survival in mice.

Authors:  S Ganai; R B Arenas; N S Forbes
Journal:  Br J Cancer       Date:  2009-10-27       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.